The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM
Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.
With Several Curative Therapies for Hepatitis C on the Market, the Research Pipeline for Prevention Continues
The authors of an influential annual report on hepatitis C research and development talk through what's new and evolving in clinical science.
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
This researcher has some ideas about what we need to do to address the problem.
Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.
Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case
The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.
Ending the HIV Epidemic Is a Team Effort. The New York City and State Health Departments Discuss Their Combined Work
Johanne Morne, M.S., and Oni Blackstock, M.D., sat down with TheBody to discuss their successes and their work to close the disparities gap.
For people taking medications for HIV prevention, HIV treatment, STIs, or transgender health care, this couple -- in life and in business -- seeks to revolutionize the pharmacy experience at TIN Rx in San Francisco.
Primary care providers need more education when it comes to PrEP, not only for them, but also for patients, who often think they need to see a specialist just to take this preventative medicine.